{
    "organizations": [],
    "uuid": "992090c5e1ea2d7e359899673225e9fafcf9dcb7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bavarian-nordic-additional-positiv/brief-bavarian-nordic-additional-positive-data-from-phase-2-study-idUSASM000K4T",
    "ord_in_thread": 0,
    "title": "BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 6 (Reuters) - BAVARIAN NORDIC A/S:\n* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE\n* SAYS TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM ITS 421 PATIENT\n* ‍PRESENCE OF ANTIBODIES IN NASAL MUCOSA SUGGEST VACCINE-INDUCED IMMUNE PROTECTION AT SOURCE OF INFECTION​\n* ‍IGA ANTIBODIES AGAINST RSV OBSERVED IN BOTH SERUM AND MUCOSA OF VACCINATED INDIVIDUALS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-06T21:43:00.000+02:00",
    "crawled": "2018-03-07T19:52:54.004+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "bavarian",
        "nordic",
        "nordic",
        "announces",
        "additional",
        "positive",
        "data",
        "phase",
        "study",
        "universal",
        "rsv",
        "vaccine",
        "say",
        "today",
        "announced",
        "additional",
        "positive",
        "data",
        "patient",
        "antibody",
        "nasal",
        "mucosa",
        "suggest",
        "immune",
        "protection",
        "source",
        "antibody",
        "rsv",
        "observed",
        "serum",
        "mucosa",
        "vaccinated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}